Logo image of CERO

CERO THERAPEUTICS HOLDINGS I (CERO) Stock Fundamental Analysis

NASDAQ:CERO - Nasdaq - US71902K4022 - Common Stock - Currency: USD

8  +0.04 (+0.57%)

After market: 7.8 -0.2 (-2.5%)

Fundamental Rating

0

CERO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. CERO has a bad profitability rating. Also its financial health evaluation is rather negative. CERO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CERO had negative earnings in the past year.
In the past year CERO has reported a negative cash flow from operations.
CERO Yearly Net Income VS EBIT VS OCF VS FCFCERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -178.24%, CERO is not doing good in the industry: 87.45% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -178.24%
ROE N/A
ROIC N/A
ROA(3y)-69.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CERO Yearly ROA, ROE, ROICCERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

CERO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CERO Yearly Profit, Operating, Gross MarginsCERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for CERO has been increased compared to 1 year ago.
There is no outstanding debt for CERO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CERO Yearly Shares OutstandingCERO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
CERO Yearly Total Debt VS Total AssetsCERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -20.19, we must say that CERO is in the distress zone and has some risk of bankruptcy.
CERO has a Altman-Z score of -20.19. This is amonst the worse of the industry: CERO underperforms 83.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.19
ROIC/WACCN/A
WACCN/A
CERO Yearly LT Debt VS Equity VS FCFCERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.73 indicates that CERO may have some problems paying its short term obligations.
CERO's Current ratio of 0.73 is on the low side compared to the rest of the industry. CERO is outperformed by 90.73% of its industry peers.
A Quick Ratio of 0.73 indicates that CERO may have some problems paying its short term obligations.
With a Quick ratio value of 0.73, CERO is not doing good in the industry: 89.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
CERO Yearly Current Assets VS Current LiabilitesCERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.88% over the past year.
EPS 1Y (TTM)35.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.77% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.59%
EPS Next 2Y39.36%
EPS Next 3Y24.77%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CERO Yearly EPS VS EstimatesCERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERO. In the last year negative earnings were reported.
Also next year CERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERO Price Earnings VS Forward Price EarningsCERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERO Per share dataCERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -100 -200 -300

4.3 Compensation for Growth

CERO's earnings are expected to grow with 24.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.36%
EPS Next 3Y24.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERO THERAPEUTICS HOLDINGS I

NASDAQ:CERO (8/11/2025, 8:00:00 PM)

After market: 7.8 -0.2 (-2.5%)

8

+0.04 (+0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners47.73%
Inst Owner Change-2.24%
Ins Owners6.24%
Ins Owner Change0%
Market Cap4.16M
Analysts82.5
Price Target45.9 (473.75%)
Short Float %3.46%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-377.43
EYN/A
EPS(NY)-22.18
Fwd EYN/A
FCF(TTM)-23.62
FCFYN/A
OCF(TTM)-23.62
OCFYN/A
SpS0
BVpS-0.63
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -178.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z -20.19
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.83%
EPS Next Y90.59%
EPS Next 2Y39.36%
EPS Next 3Y24.77%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-140.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1150.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1150.8%
OCF growth 3YN/A
OCF growth 5YN/A